MK2206 is a Akt inhibitor, is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
Related Products:
Ipatasertib; Triciribine; PHT-427; Capivasertib; Perifosine; CCT128930; AT7867; AT13148; ONC-201; Akti-1/2; SC66; Miltefosine; GSK690693